ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Epitope-Resolved Digital SERS Profiling of Structurally Dynamic Antigens via a Multi-Epitope Bispecific Antibody Framework.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Digital surface-enhanced Raman scattering (SERS) immunoassays digitize epitope binding events to achieve ultrasensitive protein detection. However, existing implementations predominantly rely on single-epitope recognition, yielding 1D molecular view of antigen structure and obscuring how conformational heterogeneity or mutation-induced changes affect epitopes. This limitation cannot be resolved simply by combining multiple monoclonal antibodies, as heterogeneous conjugation and uncontrolled binding collapse epitope-specific responses into pooled, non-assignable signals. Here, we introduce EpiCount-SERS (Epitope-Resolved Digital Counting by SERS), a multi-epitope digital SERS framework that enables epitope-resolved immunochemical profiling. The platform employs nanobody-based bispecific antibody fragments that pair epitope-specific nanobodies with a unified anti-methoxy polyethylene glycol conjugation domain, enabling orientation-controlled attachment to spectrally encoded SERS nanotags. Epitope-specific binding events are discretized into independent digital channels, allowing distinct epitopes on the SARS-CoV-2 receptor-binding domain to be interrogated in parallel. Digital enumeration across these channels generates epitope-resolved molecular fingerprints that capture information beyond single-epitope assays. EpiCount-SERS achieves sub-ng mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.